Control of endothelin-A receptor expression by progesterone is enhanced by synergy with gata2

Molecular Endocrinology

Volumn 27, Issue 6, 2013, Pages 892-908

  Zhang, Yanping ^a   Knutsen, Gregory R ^a   Brown, Matthew D ^a   Bruno Ruest, L ^a  

^a BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN A RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR B; TRANSCRIPTION FACTOR GATA 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; ENZYME ACTIVITY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; UPREGULATION;

ANIMALS; BASE SEQUENCE; FEMALE; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; PREGNANCY; PRIMARY CELL CULTURE; PROGESTERONE; PROMOTER REGIONS, GENETIC; RECEPTOR, ENDOTHELIN A; RESPONSE ELEMENTS; SEQUENCE ANALYSIS, DNA; UP-REGULATION;

EID: 84877900192     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1334     Document Type: Article

References (80)

1. Kedzierski RM, Yanagisawa M. Endothelin system: the doubleedged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851-876.
2. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485-498.
3. Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85:1159-1204.
4. Dettlaff-Swiercz DA, Wettschureck N, Moers A, Huber K, Offermanns S. Characteristic defects in neural crest cell-specific Gαq/ Gα11- and Gα12/Gα13-deficient mice. Dev Biol. 2005;282:174-182.
5. Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 1998;125:813-824.
6. Ruest LB, Xiang X, Lim KC, Levi G, Clouthier DE. Endothelin-A receptor-dependent and-independent signaling pathways in establishing mandibular identity. Development. 2004;131:4413-4423.
7. Ruest LB, Clouthier DE. Elucidating timing and function of endothelin- A receptor signaling during craniofacial development using neural crest cell-specific gene deletion and receptor antagonism. Dev Biol. 2009;328:94-108.
8. Hirata Y. Endothelin-1 receptors in cultured vascular smooth muscle cells and cardiocytes of rats. J Cardiovasc Pharmacol. 1989; 13(Suppl 5):S157-S158.
9. LaMarca B, Parrish M, Ray LF, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009;54:905-909.
10. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens. 2010;19:134-139.
11. Wendel M, Knels L, Kummer W, Koch T. Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. J Histochem Cytochem. 2006;54:1193-1203.
12. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest. 2006;36(Suppl 3): 78-88.
13. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003;97:779-784.
14. Wülfing P, Diallo R, Kersting C, et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res. 2003; 9:4125-4131.
15. Yin JJ, Mohammad KS, Käkönen SM, et al. A causal role for endothelin- 1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100:10954-10959.
16. Fujioka D, Nakamura S, Yoshino H, et al. Expression of endothelins and their receptors in cells from human periodontal tissues. J Periodontal Res. 2003;38:269-275.
17. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens. 2011;24:964-969.
18. Collett GP, Kohnen G, Campbell S, Davenport AP, Jeffers MD, Cameron IT. Localization of endothelin receptors in human uterus throughout the menstrual cycle. Mol Hum Reprod. 1996;2:439-444.
19. Bacon CR, Morrison JJ, O'Reilly G, Cameron IT, Davenport AP. ETA and ETB endothelin receptors in human myometrium characterized by the subtype selective ligands BQ123, BQ3020, FR139317 and PD151242. J Endocrinol. 1995;144:127-134.
20. Wolff K, Faxén M, Lunell NO, Nisell H, Lindblom B. Endothelin receptor type A and B gene expression in human nonpregnant, term pregnant, and preeclamptic uterus. Am J Obstet Gynecol. 1996; 175:1295-1300.
21. O'Reilly G, Charnock-Jones DS, Davenport AP, Cameron IT, Smith SK. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle. J Clin Endocrinol Metab. 1992;75:1545-1549.
22. Li P, Oparil S, Sun JZ, Thompson JA, Chen YF. Fibroblast growth factor mediates hypoxia-induced endothelin: a receptor expression in lung artery smooth muscle cells. J Appl Physiol. 2003;95:643-651; discussion 863.
23. Nilsson D, Wackenfors A, Gustafsson L, et al. PKC and MAPK signalling pathways regulate vascular endothelin receptor expression. Eur J Pharmacol. 2008;580:190-200.
24. Villeneuve A, Bernier C, Provencher PH. Regulation of endothelin- 1 and ET-A receptor expression by glucocorticoids: implications in blood pressure control. Curr Topics Steroid Res. 1999;2:69-80.
25. Villeneuve A, Gignac S, Provencher PH. Glucocorticoids decrease endothelin-A- and-B-receptor expression in the kidney. J Cardiovasc Pharmacol. 2000;36:S238-240.
26. Kutzler MA, Molnar J, Schlafer DH, Kuc RE, Davenport AP, Nathanielsz PW. Maternal dexamethasone increases endothelin-1 sensitivity and endothelin a receptor expression in ovine foetal placental arteries. Placenta. 2003;24:392-402.
27. Piekorz RP, Gingras S, Hoffmeyer A, Ihle JN, Weinstein Y. Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20α-hydroxysteroid dehydrogenase. Mol Endocrinol. 2005;19:431-440.
28. Sharma R, Bulmer D. The effects of ovariectomy and subsequent progesterone replacement on the uterus of the pregnant mouse. J Anat. 1983;137 (Pt 4):695-703.
29. Inada K, Hayashi S, Iguchi T, Sato T. Establishment of a primary culture model of mouse uterine and vaginal stroma for studying in vitro estrogen effects. Exp Biol Med (Maywood). 2006;231:303-310.
30. Palmberg L, Thyberg J. Uterine smooth muscle cells in primary culture. Alterations in fine structure, cytoskeletal organization and growth characteristics. Cell Tissue Res. 1986;246:253-262.
31. Rybak SL, Murphy RF. Primary cell cultures from murine kidney and heart differ in endosomal pH. J Cell Physiol. 1998;176:216-222.
32. Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
33. Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol. 2005;25:706-715.
34. Ruest LB, Marcotte R, Wang E. Peptide elongation factor eEF1A- 2/S1 expression in cultured differentiated myotubes and its protective effect against caspase-3-mediated apoptosis. J Biol Chem. 2002;277:5418-5425.
35. Bergeron C, Ferenczy A, Toft DO, Schneider W, Shyamala G. Immunocytochemical study of progesterone receptors in the human endometrium during the menstrual cycle. Lab Invest. 1988;59: 862-869.
36. Aparicio O, Geisberg JV, Sekinger E, Yang A, Moqtaderi Z, Struhl K. Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences in vivo. Curr Protoc Mol Biol. 2005;Chapter 21:Unit 21.23.
37. Willis D, Zhang Y, Molloy GR. Transcription of brain creatine kinase in U87-MG glioblastoma is modulated by factor AP2. Biochim Biophys Acta. 2005;1728:18-33.
38. Ye J, Cippitelli M, Dorman L, Ortaldo JR, Young HA. The nuclear factor YY1 suppresses the human γ interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. Mol Cell Biol. 1996;16:4744-4753.
39. Loots GG, Ovcharenko I. rVISTA 2.0: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res. 2004;32: W217-W221.
40. Lee EC, Yu D, Martinez de Velasco J, et al. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics. 2001;73:56-65.
41. Boron WF, Boulpaep EL. Medical Physiology: A Cellular and Molecular Approach. Philadelphia, PA: Elsevier Saunders; 2005.
42. Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci. 2011;18:6-19.
43. Davies IJ, Ryan KJ. The uptake of progesterone by the uterus of the pregnant rat in vivo and its relationship to cytoplasmic progesterone- binding protein. Endocrinology. 1972;90:507-515.
44. Haukkamaa M. Binding of progesterone by rat myometrium during pregnancy and by human myometrium in late pregnancy. J Steroid Biochem. 1974;5:73-79.
45. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/ thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451-486.
46. McDonald MW, Diokno AC, Seski JC, Menon KM. Measurement of progesterone receptor in human renal cell carcinoma and normal renal tissue. J Surg Oncol. 1983;22:164-166.
47. Bumke-Vogt C, Bahr V, Diederich S, et al. Expression of the progesterone receptor and progesterone: metabolising enzymes in the female and male human kidney. J Endocrinol. 2002;175:349-364.
48. Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21:2933-2942.
49. Schug J. Using TESS to Predict Transcription Factors Binding Sites in DNA Sequence. In: Baxevanis AD, ed. Current Protocols in Bioinformatics. New York, NY: J Wiley, Sons; 2003
50. Chalepakis G, Arnemann J, Slater E, Brüller HJ, Gross B, Beato M. Differential gene activation by glucocorticoids and progestins through the hormone regulatory element of mouse mammary tumor virus. Cell. 1988;53:371-382.
51. Connaghan-Jones KD, Heneghan AF, Miura MT, Bain DL. Thermodynamic dissection of progesterone receptor interactions at the mouse mammary tumor virus promoter: monomer binding and strong cooperativity dominate the assembly reaction. J Mol Biol. 2008;377:1144-1160.
52. Jacobsen BM, Jambal P, Schittone SA, Horwitz KB. ALU repeats in promoters are position-dependent co-response elements (coRE) that enhance or repress transcription by dimeric and monomeric progesterone receptors. Mol Endocrinol. 2009;23:989-1000.
53. Connor EE, Meyer MJ, Li RW, Van Amburgh ME, Boisclair YR, Capuco AV. Regulation of gene expression in the bovine mammary gland by ovarian steroids. J Dairy Sci. 2007;90(Suppl 1):E55-E65.
54. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor _, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol. 1991;11:5032-5043.
55. Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB. Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998;273:10696-10701.
56. Bamberger AM, Bamberger CM, Gellersen B, Schulte HM. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc Natl Acad Sci U S A. 1996; 93:6169-6174.
57. Magklara A, Smith CL. A composite intronic element directs dynamic binding of the progesterone receptor and GATA-2. Mol Endocrinol. 2009;23:61-73.
58. Yin P, Roqueiro D, Huang L, et al. Genome-wide progesterone receptor binding: cell type-specific and shared mechanisms in T47D breast cancer cells and primary leiomyoma cells. PLoS One. 2012; 7:e29021.
59. Jeong JW, Lee KY, Kwak I, et al. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology. 2005;146:3490-3505.
60. Kornberg RD. The molecular basis of eukaryotic transcription. Proc Natl Acad Sci U S A. 2007;104:12955-12961.
61. Nelson CC, Hendy SC, Shukin RJ, et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol Endocrinol. 1999;13:2090-2107.
62. Dallot E, Pouchelet M, Gouhier N, Cabrol D, Ferré F, Breuiller-Fouché M. Contraction of cultured human uterine smooth muscle cells after stimulation with endothelin-1. Biol Reprod. 2003;68: 937-942.
63. Di Liberto G, Dallot E, Eude-Le Parco I, Cabrol D, Ferré F, Breuiller-Fouché M. A critical role for PKC_ in endothelin-1-induced uterine contractions at the end of pregnancy. Am J Physiol Cell Physiol. 2003;285:C599-C607.
64. Raymond MN, Bole-Feysot C, Banno Y, Tanfin Z, Robin P. Endothelin- 1 inhibits apoptosis through a sphingosine kinase 1-dedoi: pendent mechanism in uterine leiomyoma ELT3 cells. Endocrinology. 2006;147:5873-5882.
65. Raymond MN, Robin P, De Zen F, Vilain G, Tanfin Z. Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells. Endocrinology. 2009;150:4766-4776.
66. Weston G, Trajstman AC, Gargett CE, Manuelpillai U, Vollenhoven BJ, Rogers PA. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod. 2003;9:541-549.
67. Smollich M, Wülfing P. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert Rev Anticancer Ther. 2008;8:1481-1493.
68. Ha NH, Nair VS, Reddy DN, et al. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res. 2011;71:7259-7269.
69. Smollich M, Wülfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol. 2007;5:239-248.
70. Margarit L, Griffiths A, Tsapanos V, Decavalas G, Gumenos D. Second trimester amniotic fluid endothelin concentration. A possible predictor for pre-eclampsia. J Obstet Gynaecol. 2005;25:18-20.
71. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol. 2008;198:7-22.
72. Sooriyamoorthy M, Gower DB. Hormonal influences on gingival tissue: relationship to periodontal disease. J Clin Periodontol. 1989; 16:201-208.
73. Deasy MJ, Vogel RI. Female sex hormonal factors in periodontal disease. Ann Dent. 1976;35:42-46.
74. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric. 2008;11:355-363.
75. Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.
76. Dunn N. The risk of deep venous thrombosis with oral contraceptives containing drospirenone. BMJ. 2011;342:d2519.
77. Cohen DW, Friedman L, Shapiro J, Kyle GC. A longitudinal investigation of the periodontal changes during pregnancy. J Periodontol. 1969;40:563-570.
78. Cohen DW, Shapiro J, Friedman L, Kyle GC, Franklin S. A longitudinal investigation of the periodontal changes during pregnancy and fifteen months post-partum. II. J Periodontol. 1971;42:653-657.
79. Michalowicz BS, Hodges JS, DiAngelis AJ, et al. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med. 2006; 355:1885-1894.
80. Offenbacher S, Beck JD, Jared HL, et al. Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Obstet Gynecol. 2009;114:551-559.